Actively Recruiting
Oral Metronomic Vinorelbine and PD-1 Inhibitors in Elderly Non-small Cell Lung Cancer
Led by Anhui Chest Hospital · Updated on 2025-06-27
40
Participants Needed
1
Research Sites
185 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to evaluate the efficacy and safety of oral metronomic vinorelbine and PD-1 inhibitors in elderly patients with unoperable, locally advanced or metastatic non-small-cell lung cancer. The primary end point was objective response rate (ORR), and the second end points included disease control rate (DCR), progression-free survival (PFS), and safety. Participants over 65 years old, received oral metronomic vinorelbine 40mg every week (20mg for patients over 80 years old), combined with PD-1 inhibitors every 3 weeks.
CONDITIONS
Official Title
Oral Metronomic Vinorelbine and PD-1 Inhibitors in Elderly Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients have histologically or cytologically confirmed non-small cell lung cancer with no driver gene mutations
- Age 65 years or older
- No prior first-line treatment for lung cancer
- Karnofsky Performance Status score of 70 or higher (ECOG score 0-1)
- Expected survival of at least 3 months
- Normal or near-normal major organ function including blood counts, liver, kidney, and cardiac function
- Good compliance and ability to cooperate with follow-up
You will not qualify if you...
- Patients who have received prior treatment for lung cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Anhui Chest Hosptial
Hefei, Anhui, China, 230022
Actively Recruiting
Research Team
M
Maojing Guan, Doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here